Medtronic Q1 Beat, Raises FY27 Guidance
Analysis based on 6 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026
Medtronic's strong Q1 results and raised guidance signal robust demand for its medical devices, likely boosting investor confidence in the company and the broader medical device sector. The stock rose in pre-market trading, reflecting positive market reaction to the earnings beat and strategic investments in surgical robotics and structural heart technologies.
Medtronic reported fiscal Q1 2027 results that beat expectations, with net income of $1.47 billion ($1.14 per share) versus $1.04 billion ($0.81 per share) a year ago. Adjusted EPS was $1.45, up from $1.26. Net sales grew 13.7% to $9.76 billion, aided by an extra fiscal week that contributed about $570 million to organic growth. All four business segments posted double-digit growth: Cardiovascular up 19.5%, Neuroscience up 10.3%, Medical Surgical up 10.0%, and Diabetes up 16.9%. Operating margin improved 130 basis points to 18.1%. The company raised its FY2027 adjusted EPS guidance to $5.94-$6.00 and organic revenue growth to 7.25%-7.75%, up from prior $5.90-$6.00 and 6.75%-7.25%. CFO Thierry Pieton attributed the beat to strong operating performance and disciplined financial management. Additionally, Medtronic announced a strategic partnership with Cornerstone Robotics, investing approximately $700 million for distribution rights to its Sentire surgical system in select markets, and a strategic investment of up to $80 million in Pi-Cardia Ltd., with an option to acquire Pi-Cardia for up to $210 million plus earn-outs upon achieving milestones. In pre-market trading, MDT rose about 3-5% on the New York Stock Exchange.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard